Background and objective: Non-specific interstitial pneumonia (NSIP) has heterogeneous characteristics in terms of background, disease behaviour and prognosis. This study of fibrotic NSIP (f-NSIP) aimed to elucidate prognosis and disease behaviour from the viewpoint of clinical background and determine whether long-term change of pulmonary function could provide useful prognostic information. Methods: We analysed the medical records of 157 consecutive patients diagnosed with f-NSIP by surgical lung biopsy. Disease behaviour was categorized into two groups depending on long-term change of pulmonary function: progressive type (relative ≥5%/year decline in the slope of forced vital capacity and/or relative ≥7.5%/ year decline in the slope of %diffusing capacity of lung carbon monoxide) or stable type. Predictors of disease behaviour and prognosis were determined using logistic and Cox regression models.
INTRODUCTION
In the recent American Thoracic Society (ATS)/European Respiratory Society (ERS) statement, [1] [2] [3] idiopathic non-specific interstitial pneumonia (NSIP) is a distinct clinical entity subcategorized into chronic fibrosing interstitial pneumonia and idiopathic pulmonary fibrosis (IPF) because most cases of idiopathic NSIP have a predominantly fibrotic pattern with rare cases of cellular NSIP. 3, 4 Because the prognosis is variable, some fibrotic NSIP (f-NSIP) patients evolve to end-stage fibrosis despite all treatment, as with IPF. 5, 6 However, prognostic factors and disease behaviour remain to be clarified in comparison to IPF. 
SUMMARY AT A GLANCE
Non-specific interstitial pneumonia (NSIP) has heterogeneous characteristics in terms of background, disease behaviour and prognosis. Some patients with idiopathic fibrotic NSIP with or without interstitial pneumonia with autoimmune features (IPAF) showed progressive disease despite therapy.
Importantly, NSIP is heterogeneous, and outcomes of NSIP are influenced by its cause including connective tissue disease (CTD), hypersensitivity pneumonitis and undifferentiated CTD (UCTD). [7] [8] [9] Classification as UCTD with a clinical flavour of CTD associated with NSIP is a useful concept to identify the subgroup of idiopathic NSIP patients with good prognosis. 9 New terminology of 'interstitial pneumonia with autoimmune features (IPAF)' was recently proposed. 10 However, it is not clear in f-NSIP whether disease behaviour and prognosis of IPAF are similar to those of CTD and idiopathic.
An approach based on patterns of disease behaviour is useful to estimate prognosis of idiopathic f-NSIP. 3 These disease behaviours should be evaluated according to symptomatic decline, disease progression on high-resolution computed tomography (HRCT) and pulmonary function trend. In usual interstitial pneumonia (UIP)/IPF, changes in forced vital capacity (FVC) are a reliable, valid and responsive measure of clinical status used as the primary endpoint in pivotal treatment studies. [11] [12] [13] However, the current progressive fibrosing interstitial lung disease (PF-ILD) study, which is evaluating efficacy and safety of nintedanib in patients with progressive fibrosing interstitial lung disease (ILD) (including f-NSIP) other than IPF, set annual rate of decline in FVC as the primary endpoint. 14 The present study of idiopathic f-NSIP aimed to clarify (i) prognosis and disease behaviour from the viewpoint of the clinical background of idiopathic (non-IPAF), IPAF f-NSIP and connective tissue disease associated with interstitial lung disease (CTD-ILD), and (ii) whether long-term change in pulmonary function could provide useful prognostic information.
METHODS

Study sample
This study was approved by the institutional review board of Kanagawa Cardiovascular and Respiratory Center (KCRC-16-0001). We selected 204 consecutive patients with a histological pattern of f-NSIP on surgical lung biopsy (SLB) examined at the Center between January 2001 and April 2016 (Fig. 1) . SLB slides were reviewed by two pulmonary pathologists (K. Okudela, T. Takemura) blinded to patient clinical and radiological information. Histologic patterns were classified according to previously defined criteria for idiopathic interstitial pneumonia (IP). 1, 2 Two radiologists (T. Iwasawa, S. Iso) blinded to patient clinical data reviewed HRCT scans for consensus of ILD diagnosis. Patients were classified as presenting a HRCT pattern either 'suggestive or consistent with NSIP' or 'suggestive of UIP'. 1, 3 Initial disagreements were resolved by discussion.
After multidisciplinary discussion between respiratory physicians, radiologists and pathologists, 10 patients diagnosed as having other than idiopathic NSIP (including IPAF) or CTD with f-NSIP were excluded. Moreover, after re-review of the SLB specimens independently using the histologic criteria for diagnosis according to the new 2013 ATS/ERS classification, 3 the diagnosis in 37 patients changed from f-NSIP to unclassifiable IP. With further discussion, the histological pattern in seven of these patients was considered to show the relatively conspicuous coexistence of a UIP pattern. Other diagnoses in the remaining 30 patients included acute inflammatory findings such as organizing pneumonia and alveolar epithelial injury and interstitial cellular infiltration surrounded by hyaline membrane collapse, which was more prominent in unclassifiable IP than in f-NSIP as we reported previously. 15 We thought these subjects were comparable to a variant of organizing pneumonia with supervening fibrosis or a fibrosing variant of organizing pneumonia. 3, 16 Patients with CTD fulfilled each of the standard criteria. [17] [18] [19] [20] [21] IPAF was confirmed when they had the clinical and/or serological domain specified by the ERS/ATS task force. 10 Anti PM-Scl and anti-MDA-5 of the serological domain were not included because our institution could not routinely evaluate these parameters. Ten of the IPAF subjects developed manifestations of CTD during their follow-up (3-80 months) and were included as CTD-ILD patients.
Data collection
Baseline clinical measures were obtained within 3 months of the initial diagnosis of ILD at our hospital. A broad panel of autoantibodies was evaluated in the initial workup or during follow-up. For anti-aminoacyl transfer RNA (tRNA) synthetase antibodies (anti-Jo-1, EJ, PL-7, PL-12, OJ, KS), routine-conserved serum of each patient was measured by RNA-immunoprecipitation and protein-immunoprecipitation assays.
Disease behaviour
First, treatment response at 1 year (including at 1 year AE 6 months) based on changes in pulmonary function testing (PFT) results was defined as the %change of the initial value. Patients were assigned to the Improved or Worsened group based on increases or decreases, respectively, of >10% in FVC and >15% %diffusing capacity of lung carbon monoxide (%DL CO ). 15, 22 Second, if PFT was repeatedly performed at least 12 months after the initial assessment, long-term change in respiratory function was evaluated. We created a chart of the time data of FVC and %DL CO via scatter plot for each patient and then added a regression line. The intercept (steepness of the line) and slope (location where the line intersects an axis) of the curves for FVC and %DL CO of each patient were extracted. Finally, based on these studies, 14, 22 because NSIP is less progressive than UIP, we defined 'progressive type' disease as a relative ≥5%/year decline in the slope of FVC from baseline FVC (intercept) and/or relative ≥7.5%/year decline in the slope of %DL CO from baseline %DL CO (intercept), and 'stable type' disease as not fulfilling the above definition.
as appropriate. We investigated potential risk factors of mortality with each variable chosen for entry into univariate Cox regression analysis and performed multivariate Cox regression analysis with forward variable selection. The Kaplan-Meier method and log-rank test were used to display and compare survival curves for the cohort stratified for each group. Analysis of disease behaviour based on FVC and %DL CO over time was performed with linear mixed-effects models in which separate fits for subjects with idiopathic (non-IPAF) f-NSIP, IPAF f-NSIP and CTD-ILD were analysed. Each model included random terms for intercept and slope (for time from diagnosis) to account for the data structure (repeated measures over time within subject). Next, we performed logistic regression analysis to identify independent factors associated with progressive type disease behaviour. We considered P < 0.05 to represent statistical significance. All data were analysed with SPSS version 22.0 (IBM Japan, Tokyo, Japan).
RESULTS
Patient characteristics
We identified 157 subjects with pathological f-NSIP: 35 with idiopathic (non-IPAF) f-NSIP, 58 with IPAF f-NSIP and 64 with CTD-ILD at final classification ( Fig. 1) . Nineteen IPAF patients (32.8%) had a positive at least either one of clinical domain (Table S1 in Supplementary Information). Significantly more idiopathic f-NSIP patients with or without IPAF were male and had noticeable symptoms with dyspnoea on exertion and a lower FVC (%predicted) than did CTD-ILD patients. Compared with CTD-ILD patients, those with idiopathic (non-IPAF) f-NSIP were significantly more frequently current or ex-smokers, whereas IPAF f-NSIP patients tended to more frequently be never-smokers than the idiopathic (non-IPAF) f-NSIP patients (Table 1  and Table S1 in Supplementary Information).
Emphysema was significantly more frequently observed in idiopathic (non-IPAF) and IPAF f-NSIP patients (P = 0.002).
Clinical course and disease behaviour
No patients died within 1 year or underwent transplantation. Scatter plots of FVC and %DL CO for each group are shown along the time axis (Fig. S1 in Supplementary Information). Patients with this disease were significantly more likely to use pirfenidone and have idiopathic (non-IPAF) f-NSIP, emphysema on HRCT and poorer treatment response at 1 year (Table 2) . Idiopathic (non-IPAF) f-NSIP patients were significantly less likely to have stable type than those with IPAF f-NSIP and CTD-ILD (P = 0.012) (Table S2 in Supplementary Information). Linear mixed-effects analysis showed that the declines in the slopes of FVC and % DL CO were not significantly different between the three stable type groups ( Fig. 2A, B) . In progressive type, the slopes of FVC in idiopathic (non-IPAF) f-NSIP and IPAF f-NSIP were significantly steeper than that in CTD-ILD (Fig. 2C) . The slopes of %DL CO also tended to be steeper in idiopathic (non-IPAF) f-NSIP and IPAF f-NSIP than in CTD-ILD (Fig. 2D ).
Predictive factors of progressive-type disease
Idiopathic (non-IPAF) f-NSIP, poor treatment response at 1 year and emphysema on HRCT were significant factors predicting progressive type by univariate analysis (Table S3 in Supplementary Information). Multivariate analysis showed only poor treatment response at 1 year to be an independent predictor of progressive type.
Mortality
Death from any cause occurred in 29 patients (18.5%) over a median follow-up period of 5.61 AE 3.89 years ( Table S2 in Supplementary Information). Patient survival was better for IPAF than for idiopathic (non-IPAF) f-NSIP (P < 0.001) but was similar to that for CTD-ILD (P = 0.920) (Fig. 3A) . Cumulative 5-and 10-year survival rates were 64.9% and 37.1% in idiopathic (non-IPAF) f-NSIP, 95.4% and 70.2% in IPAF f-NSIP, 88.5% and 82.1% in CTD-ILD, and 85.0% and 59.5% in all idiopathic f-NSIP patients, respectively. Treatment response at 1 year showed no significant difference in survival between the Improved, Stable and Worsened groups (P = 0.427) (Fig. 3B) . Patients with progressive type had poorer survival than those with stable type (P < 0.001) (Fig. 3C ), and patients with positive radiological findings of emphysema had significantly worse survival than those without emphysema (P = 0.003) (Fig. 3D) .
Male, older age, current or ex-smoker, idiopathic (non-IPAF) f-NSIP, symptoms of dyspnoea on exertion, no presence of clinical domain, lower FVC (%pre-dicted), lower DL CO (%predicted), higher composite physiological index and emphysema on HRCT were significant predictors of mortality by univariate analysis. Multivariate Cox proportional hazards analysis showed idiopathic (non-IPAF) f-NSIP and progressive type to be negative prognostic factors of mortality (Table 3) .
DISCUSSION
This study revealed two important points. First, an IPAF designation was useful in identifying the Prognosis of fibrotic NSIP subgroup with good prognosis in idiopathic f-NSIP. Second, disease behaviour evaluated by longitudinal decline in the slopes of FVC and %DL CO was a useful predictive marker of prognosis in f-NSIP, and progressive type disease could be a predictor of poor prognosis. Our overall 5-year survival rate of 85.0% for idiopathic f-NSIP (including IPAF) compared favourably with previous reports (74-100%). 4, 23, 24 Idiopathic (non-IPAF) f-NSIP was a negative prognostic factor for allcause mortality, and survival was poorer than that for IPAF f-NSIP and CTD-ILD. This result was similar to a previous UCTD cohort. 9 However, another study recently reported that survival for IPAF was worse than that for CTD-ILD, 25 but the results were inconsistent because multiple radiological and pathological patterns such as UIP pattern were included. Essential points regarding our results are as follows. When IPAF f-NSIP patients were analysed altogether, their prognosis for overall survival was good and not significantly different from that of the CTD-ILD patients. However, when considering disease behaviour based on pulmonary function change focusing on progressive type, the prognosis of some of the IPAF patients and the idiopathic (non-IPAF) f-NSIP patients was poorer than that of the CTD-ILD patients. Most patients with progressive type were on medications for ILD. Thus, some idiopathic f-NSIP patients with or without IPAF tended to show poor disease behaviour despite therapy as previously reported. 1 , forced expiratory volume in 1 s; f-NSIP, fibrotic non-specific interstitial pneumonia; FVC, forced vital capacity; ILD, interstitial lung disease; IPAF, interstitial pneumonia with autoimmune features; PFT, pulmonary function tests; RV, residual volume; TLC, total lung capacity; UIP, usual interstitial pneumonia.
2,3
Do patients with poor outcome include both patients with idiopathic (non-IPAF) f-NSIP and also those with IPAF? A significant predictive factor of mortality by univariate analysis in common with that of progressive type was emphysema on HRCT. Some reports suggested an influence of smoking in NSIP patients. 3, 26 Although emphysema has not been scored systemically, emphysema may influence some f-NSIP patients with poor prognosis.
A further novel aspect of our study was whether declines in FVC and %DL CO are possible prognostic predictors of f-NSIP. Some reports particularly on UIP/IPF strongly and logically support the use of FVC as a valid, robust measure that fulfils the criteria for an ideal clinical endpoint. 22, [27] [28] [29] Zappala et al. reported that marginal deterioration in FVC (5-10%) and DL CO (7.5-15%) at 6 months in idiopathic f-NSIP did not provide useful prognostic information, 22 but other investigators reported that a change in FVC at 12 months was a good predictor of mortality, with substantially higher mortality found in f-NSIP patients with >10% decline in FVC. 23 However, unlike UIP/IPF, because PFT results in some f-NSIP patients deteriorated gradually after initial improvement by medical intervention, we also thought it questionable to compare PFT trends with baseline PFT data before therapy. In fact, treatment response at 1 year was not a significant prognostic factor in our cohort. We also analysed disease behaviour relating to PFT by using regression lines and determining the declining slope from the intercept as the estimated baseline for all available data over time. Progressive type as defined here was shown to predict poor prognosis by , Idiopathic (non-IPAF);
, idiopathic (IPAF); , CTD-ILD. %DL CO , %diffusing capacity of lung carbon monoxide; CTD, connective tissue disease; f-NSIP, fibrotic non-specific interstitial pneumonia; FVC, forced vital capacity; ILD, interstitial lung disease; IPAF, interstitial pneumonia with autoimmune features multivariate analysis, and its presence might be useful for predicting mortality and for clinical decision making and therapeutic trials.
About one-third of our patients with progressive type disease received pirfenidone, and most of these patients also received anti-inflammatory agents for progressive and refractory disease. However, whether anti-fibrotic agents are actually effective in progressive non-IPF ILD remains unknown, and additional clinical research (such as the PF-ILD trial 14 ) is greatly needed to identify effective therapies for non-IPF ILD associated with progressive fibrosis.
30
The limitations of this study are as follows. First, it was a retrospective, single-centre study. Second, patients with chronic hypersensitivity pneumonitis were excluded because their number was small. Thus, some patients who could not be diagnosed as having this disease might be included. Third, not all patients were evaluated for all CTD-related autoantibodies or clinically examined by rheumatologists. However, the chest clinicians carry out screening while always keeping routine examination of each CTD-related autoantibody in mind, even if the patients with ILD have no symptoms suspicious of CTD. Furthermore, if the patients have autoantibodies related to CTD, we usually consult the rheumatologists to determine whether the diagnosis of CTD can be fulfilled. Fourth, we could not determine whether the clinical diagnosis of either CTD-ILD or IPAF impacted treatment decisions and as such the natural course. Fifth, although %DL CO decline Figure 3 Kaplan-Meier survival curves of all-cause mortality. (A) Survival in patients with idiopathic NSIP was worse than that in the patients with IPAF and with CTD-ILD (P < 0.001). Survival in patients with IPAF was not significantly different from that in CTD-ILD (P = 0.920). (B) The survival curves for patients with each type of treatment at 1 year were not significantly different (P = 0.920). (C) The patients with progressive type disease showed poorer survival than those with stable type disease (P < 0.001). (D) The survival curve of patients with positive radiological finding of emphysema was significantly worse than that of the patients without emphysema (P = 0.003).
, may indicate possible pulmonary hypertension, we could not analyse this, and it would be an issue for future investigation.
In conclusion, our study suggested that idiopathic (non-IPAF) f-NSIP may be a negative prognostic factor for all-cause mortality, and an IPAF diagnosis can be useful for identifying good prognosis in idiopathic f-NSIP. However, some idiopathic f-NSIP patients with or without IPAF showed progressive disease despite therapy. The presence of progressive type disease defined by the slope of FVC and %DL CO could be a useful predictor of poor prognosis in f-NSIP and may help in assessing appropriate strategies to diagnose and treat f-NSIP. 
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Figure S1
Changes in FVC and %DL CO during follow-up. 
